TEST CATALOG ORDERING & RESULTS SPECIMEN HANDLING CUSTOMER SERVICE EDUCATION & INSIGHTS
Test Catalog

Test ID: FIVCZ    
Isavuconazole (CRESEMBA) LC-MS/MS

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Isavuconazole is for the treatment of life threatening fungal infections, specifically invasive aspergillosis and invasive mucormycosis. There is a significant need for alternative antifungal therapies that address some of the limitations of voriconazole, such as reduced potential for nephrotoxicity for the intravenous formulation, in addition to other dose-related toxicities. Given the difficulty in diagnosis and similarity with which infections may present, having an antifungal that is effective for both indications would be particularly useful to physicians treating immunocompromised patients.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

0.1-10. mcg/mL

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Astellas Pharma US, Inc., CRESEMBA Package Insert.

2. von Mach MA1, Burhenne J, Weilemann LS. 2006. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol. 2006 6:6.

3. Pascual A1, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 46(2):201-11.

4. Andes D, Pascual A, Marchetti O. Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications. Antimicrob Agents Chemother. 2009 Jan; 53(1):24–34.

5. Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother. 2008 Jan; 61(1):17–25.

6. Pappas PG1, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009 Mar 1; 48(5):503-35.

7. Walsh TJ1, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008 Feb 1; 46(3):326-60.